StageDebt | Dead
About Elcelyx Therapeutics
Elcelyx Therapeutics is developing therapeutic agents based on the finding that modulation of the neuro-enteroendocrine system of the gut, including L-cells, amplifies the release of hormones such as those that play an important role in glucose regulation. This discovery affords a potentially safety advantaged platform to develop therapies as well as re-position existing therapies to meet serious unmet needs. Elcelyx's Metformin Delayed Release (Metformin DR) releases metformin in the gut instead of systemically, reducing bioavailability while still achieving efficacy. In two previous Phase 2 studies, Metformin DR lowered glucose and was well tolerated in patients with type 2 diabetes.
Missing: Elcelyx Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Elcelyx Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Elcelyx Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Elcelyx Therapeutics is included in 2 Expert Collections, including Omics.
Elcelyx Therapeutics Patents
Elcelyx Therapeutics has filed 18 patents.
The 3 most popular patent topics include:
- G protein coupled receptors
Diabetes, Piperidines, Piperazines, G protein coupled receptors, Muscarinic antagonists
Diabetes, Piperidines, Piperazines, G protein coupled receptors, Muscarinic antagonists
Latest Elcelyx Therapeutics News
Oct 6, 2018
Summary Elcelyx Therapeutics Inc Elcelyx is a developer of novel therapies for the treatment of type 2 diabetes and other unmet medical needs. The company develops pharmaceutical agents that are designed to modulate the gut neuroendocrine system including the Lcell. Its products include Metformin DR, a delayedrelease formulation of metformin that is designed to release metformin primarily in the distal small intestine and restrict metformin to the bowel. The company's Metformin DR is used in glucose lowering for type 2 diabetes patients with renal impairment. Elcelyx is headquartered in San Diego, California, the US. Elcelyx Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Elcelyx Therapeutics Frequently Asked Questions (FAQ)
Where is Elcelyx Therapeutics's headquarters?
Elcelyx Therapeutics's headquarters is located at 11975 El Camino Real, San Diego.
What is Elcelyx Therapeutics's latest funding round?
Elcelyx Therapeutics's latest funding round is Debt.
How much did Elcelyx Therapeutics raise?
Elcelyx Therapeutics raised a total of $90.34M.
Who are the investors of Elcelyx Therapeutics?
Investors of Elcelyx Therapeutics include Kleiner Perkins Caufield & Byers, GSM Fund, Morgenthaler Ventures, Clough Global, Sailing Capital and 3 more.
Who are Elcelyx Therapeutics's competitors?
Competitors of Elcelyx Therapeutics include Affibody, Biocytogen, Biolog, PPD, ForSight VISION4 and 11 more.
Compare Elcelyx Therapeutics to Competitors
Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.
BioSkills is a service company founded to provide its customers with basic and advanced skills in life science and biotech area. BioSkills achieves its primary objectives by developing original formation initiatives in order to spread relevant knowledge base.
Martin-Protean is a biotechnology company that determines protein structure using chemical cross-linking and mass spectrometry. Its technology aims to provide insight into protein structure, facilitating drug design and discovery. Its products can be used by the pharmaceutical and biotechnology sectors as well as the NIH, national, and academic labs.
Ellipsis Biotherapeutics develops, fabricates, and processes drugs in pharmaceutical preparations for human or veterinary use. It provides single nucleotide polymorphism (SNP) genotyping solutions to a variety of clients in academic, government, and industrial research settings Ellipsis Biotherapeutics was founded in 1997 and is based in Toronto, Canada.
MI Research, Inc. specializes in Biotech instrumentation with excellent visualization capabilities in the area of protein crystal growth and blood viscosity measurements. MI aims to offer fluorescence base protein crystallization prescreening service and biotech instruments like blood viscometers. MI's expertise is in optics and biochemistry.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.